Search

everythinglearnresearchcommunity

for

Search:↓

Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.

The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

Male hormones, particularly DHT, are linked to male pattern hair loss, and treatments like finasteride can help, but they don't work for postmenopausal women's hair loss, which may have different causes.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

The WNT signaling pathway is important in many diseases and targeting it could offer new treatments.

PLD is an effective and safer alternative for treating breast cancer.

New butyric acid prodrugs show promise for cancer treatment, anemia management, and protecting hair from chemotherapy damage.

Scalp cooling can prevent chemotherapy-induced hair loss, and certain treatments can speed up hair regrowth, but more research is needed for better treatments.

Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

A blood pressure drug, diltiazem, may also help treat influenza.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.

The consensus document recommends a comprehensive treatment plan for Hidradenitis Suppurativa, including various medications, surgery, lifestyle changes, and the need for more research and resources.

Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.

Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.

Microneedle technology is beneficial for drug delivery and could make vaccinations cheaper and more accessible.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

New male hormonal contraceptives show promise but need more research on long-term effects and funding for larger trials.

Liposomal anthracyclines are effective and safer for treating multiple myeloma, especially in elderly patients.

New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.

New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

New patents show progress in developing drugs targeting the Wnt pathway for diseases like cancer and hair loss.

Rivaroxaban can cause liver injury, allergic reactions, blood vessel inflammation, and hair loss, but these side effects are rare.

Many potential alopecia treatments need more testing to confirm they promote acceptable hair growth with minimal side effects.

Interleukin-2 treatment improved hair growth, sexual function, and reduced fungal infection in a patient with thymoma-related symptoms.

Korean hair is typically thicker with a slower growth rate, and treatments like Dutasteride are effective for male pattern hair loss without major side effects.